OncoMatch/Clinical Trials/NCT06010875
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Is NCT06010875 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CD70 CAR-T cells and CD70 CAR-T cells for renal cell carcinoma.
Treatment: CD70 CAR-T cells · CD70 CAR-T cells — This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Ovarian Cancer
Cervical Cancer
Tumor Agnostic
Biomarker criteria
Required: CD70 overexpression (IHC 3+)
positive tumor CD70 expression (tumor CD70 positive (IHC 3+) confirmed by histology or pathology)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tyrosine kinase inhibitor
at least after TKI/PARPi, anti-vascular drug treatment is ineffective
Must have received: PARP inhibitor
at least after TKI/PARPi, anti-vascular drug treatment is ineffective
Must have received: anti-vascular drug
at least after TKI/PARPi, anti-vascular drug treatment is ineffective
Cannot have received: anti-CD70 therapy
Received anti-CD70 drug treatment before screening
Lab requirements
Blood counts
neutrophils 1.0×10^9/L, platelets 75×10^9/L, hemoglobin 80g/L
Kidney function
serum creatinine≤2.0×ULN
Liver function
ALT and AST ≤2.0×ULN (≤3.0×ULN with liver tumor infiltration); Total bilirubin ≤2.0×ULN (≤3.0×ULN with Gilbert syndrome or liver tumor infiltration)
Cardiac function
echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram
The functions of important organs are basically normal: Hematopoietic function: neutrophils 1.0×10^9/L, platelets 75×10^9/L, hemoglobin 80g/L; Cardiac function: echocardiography showed cardiac ejection fraction ≥50%, and no obvious abnormality was found on electrocardiogram; Renal function: serum creatinine≤2.0×ULN; Liver function: ALT and AST ≤2.0×ULN (for patients with liver tumor infiltration, it can be relaxed to ≤3.0×ULN); Total bilirubin ≤2.0×ULN (Gilbert syndrome or combined liver tumor infiltration can be relaxed to ≤3.0×ULN); Oxygen saturation > 92% in non-oxygen state.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify